What Herasight’s Embryo Screening Reveals About Genetic Leverage
Silicon Valley's fertility tech startups are turning IVF into a high-stakes genetic selection system. Herasight, emerging from stealth in 2025, leverages polygenic screening to assess embryos’ risks for dozens of diseases and traits, enabling parents to make choices once unimaginable.
This matters because the typical embryo selection is no longer about chance but about using vast genomic data sets to systematically reduce health risks and influence characteristics like height and IQ.
But the real leverage isn’t just genetic insight; it's the ability to integrate this data-driven screening seamlessly into any IVF clinic workflow, allowing scaling without rebuilding the medical infrastructure. This is how Herasight and similar startups create compounding advantage beyond traditional reproductive medicine.
“Systems that personalize genetics at scale will reshape family planning — it’s about redesigning biology with data,” says Michael Christensen, Herasight’s cofounder.
Challenging Traditional Views on IVF and Embryo Selection
The prevailing belief is IVF is primarily a medical tool for infertility, focused on a few chromosomal abnormalities and basic embryo viability checks. Critics say more advanced screening is hype with limited real-world impact.
That underestimates how embedding extensive genome sequencing and polygenic risk scoring transforms IVF into a platform that controls biological uncertainty early. This goes beyond simple selection of embryos toward actively shaping the input to pregnancy outcomes.
Unlike legacy methods focused on single-gene mutations or trisomies, Herasight sequences entire genomes and analyzes thousands of markers. This capability isn't a minor upgrade; it represents a systemic shift from reactive testing to predictive design, unlocking leverage by compounding risk reductions over multiple conditions simultaneously.
This reframes IVF's role from purely therapeutic to strategic asset allocation in reproductive health, a perspective emerging only because of breakthroughs in rapid genome sequencing and data interpretation advancements linked to AI.
For reference, startups like Orchid Health pursue similar goals but emphasize data completeness and disease prevention over traits, illustrating variation in strategic positioning within the same industry.
Genetic Screening as a Scalable System, Not Just a Service
Herasight’s model exemplifies a rare form of leverage: a platform approach that decouples expert genetic analysis from IVF clinical bottlenecks. Their technology works with any IVF clinic, avoiding costly integrations or proprietary systems that limit scale.
This «plug-and-play» method enables acceleration in mass adoption by removing infrastructure constraints faced by traditional specialty labs, decreasing costs and turnaround times.
The company’s own research shows a 20%-44% reduction in disease risks when choosing among just five embryos. While independent validation remains pending, publishing detailed methods reveals a commitment to transparency—an unusual position for early-stage life sciences startups.
Compare that to competitors who require proprietary clinical environments or focus narrowly on single disorders, which limits growth potential and fails to deliver cumulative risk reduction advantages across multiple health dimensions.
Within this system, founders like Michael Christensen intentionally use data-driven tradeoffs: opting to reduce cancer risk might simultaneously lower depression or autoimmune risks due to positive genetic pleiotropy— a genetic correlation leveraged to maximize impact.
Implications for Reproductive Health and Tech Investors
The biggest constraint now is data interpretation: AI models require genome sequences from nearly a billion people to refine predictive accuracy for complex traits, meaning the current generation is an imperfect but scalable foundation.
Investors like Brian Armstrong of Coinbase and Sam Altman are already backing embryo-editing startups, signaling a future shift from screening to editing, where genetic leverage compounds exponentially by altering DNA before implantation.
For operators thinking about leverage, the key insight is this: controlling the genome interpretation layer via data science, software integration, and scalable clinic partnerships creates a moat far more durable than owning IVF hardware or delivering medical procedures.
Other fertility tech firms and regional markets ignoring this shift face commoditization, while leaders unlock new strategic dimensions in family planning by turning genomics into a platform business.
“Genetic screening isn’t about perfect babies; it’s about redesigning risk landscapes with data-driven confidence,” reflects Orchid Health’s CEO Noor Siddiqui.
Related Tools & Resources
As the article emphasizes the transformational power of data in fertility tech, leveraging AI for genetic analysis is crucial. Platforms like Blackbox AI are essential for developers seeking to create advanced coding solutions that streamline genetic data interpretation, ultimately enhancing predictive models and applications in reproductive health. Learn more about Blackbox AI →
Full Transparency: Some links in this article are affiliate partnerships. If you find value in the tools we recommend and decide to try them, we may earn a commission at no extra cost to you. We only recommend tools that align with the strategic thinking we share here. Think of it as supporting independent business analysis while discovering leverage in your own operations.
Frequently Asked Questions
What is polygenic screening in embryo selection?
Polygenic screening assesses embryos’ genetic risks for dozens of diseases and traits by analyzing thousands of genetic markers, enabling parents to make informed choices beyond simple viability or chromosomal checks.
How does modern IVF genetic screening differ from traditional methods?
Modern genetic screening uses extensive genome sequencing and polygenic risk scoring to predict risks across multiple conditions simultaneously, unlike traditional methods that focus on single-gene mutations or basic chromosomal abnormalities.
What advantages do platform-based genetic screening models offer IVF clinics?
Platform models decouple genetic analysis from clinic workflows, allowing seamless integration with any IVF clinic without costly infrastructure changes, reducing costs and turnaround times while enabling scalable adoption.
How much can disease risk be reduced by selecting embryos using advanced genetic screening?
Research shows choosing among five embryos with polygenic screening can reduce disease risks by 20% to 44%, compounding benefits across various health conditions.
What are the current limitations in embryo genetic screening technology?
The main constraint is data interpretation accuracy, requiring nearly a billion genome sequences to refine AI models for complex trait prediction; current methods provide a scalable but imperfect foundation.
How might genetic leverage in embryo screening evolve in the future?
Investors are backing embryo-editing startups, which may shift from screening to DNA editing before implantation, potentially compounding genetic leverage exponentially by directly altering embryos’ genomes.
Why is controlling the genome interpretation layer important for fertility tech?
Controlling genome interpretation with data science and software integration creates a sustainable competitive moat more durable than owning IVF hardware or providing medical procedures.
What distinguishes companies like Herasight and Orchid Health in the fertility tech space?
Herasight emphasizes polygenic trait screening and scalable platform integration, while Orchid Health focuses on data completeness and disease prevention, reflecting strategic variation within embryo genetic testing.